Dr. Schor of the National Institutes of Health and Deputy Director of the National Institute of Neurological Disorders and Stroke has no relevant financial relationships to disclose.)
Dr. Packer of George Washington University and Children’s National Health System received honorariums from AstraZeneca and Novartis as an advisory board member.)
This article includes discussion of sequelae of surgery, radiation therapy, chemotherapy, and immunotherapy in patients with central nervous system (CNS) tumors. The foregoing terms may include synonyms, similar disorders, variations in usage, and abbreviations.
Short- and long-term complications of antineoplastic treatment of brain tumors are poorly understood and contribute greatly to the morbidity of these neoplasms. In this updated article, the author discusses the complications and long-term sequelae of treatment for brain tumors. Surgery, radiation therapy, chemotherapy, and immunotherapy are considered; treatment of complications and comorbidities of brain tumors (eg, antiseizure medications for symptomatic seizure prevention) are considered elsewhere in Medlink Neurology.
Historical note and terminology
The impact of tumors of the CNS on patients results not only from their high morbidity and mortality rates, but also from the sequelae of the tumors themselves and the treatment thereof. Neurocognitive sequelae are perhaps the most problematic of the effects of the treatment of CNS tumors; they can occur in both children and adults. Symptomatic epilepsy, motor and sensory dysfunction, and vascular changes also occur as early or remote effects of treatment.
The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.
If you are a subscriber, please log in.
If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.